Dr Reddy's launches first-to-market store-brand equivalent of Allegra-D 24 HR in the U.S. Market

25 Jul 2022 , 09:57 AM

Dr Reddy’s Laboratories announced the first-to-market release of Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D 24 HR in the United States, as approved by the Food and Drug Administration (USFDA).

Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories commented, “This first-to-market launch demonstrates our extensive capabilities and our ongoing efforts to provide high-quality, low-cost store-brand alternatives for our customers and patients.”

Dr. Reddy’s OTC Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP is an over-the-counter antihistamine and nasal decongestant used to treat nasal and sinus congestion caused by colds or allergies. It provides temporary relief from sneezing, runny nose, itchy, watery eyes, and itchy nose or throat caused by allergies.

According to IRI, Allegra-D 24 HR had approximately $45 million in retail sales in the United States as of May 2022.

At around 10.00 AM, Dr Reddys Laboratories was currently trading at Rs4,321 down by Rs53.5 or 1.22% from its previous closing of Rs4,374.50 on the BSE. The scrip opened at Rs4,384.90 and has touched intraday high and low of Rs4,389.95 and Rs4,300 respectively.